---
title: "ARGX: Q2 revenue up 60% YoY, VYVGART expands in MG/CIDP, pipeline and financials remain strong"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293638677.md"
description: "Q2 2026 saw record revenue growth of 60% year-over-year, driven by VYVGART's strong performance in MG and CIDP, including the seronegative MG launch. Pipeline progress and label expansions are set to sustain long-term growth, with robust financials and disciplined capital allocation.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-23T15:04:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293638677.md)
  - [en](https://longbridge.com/en/news/293638677.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293638677.md)
generator: "portal-rs"
---

# ARGX: Q2 revenue up 60% YoY, VYVGART expands in MG/CIDP, pipeline and financials remain strong

Q2 2026 saw record revenue growth of 60% year-over-year, driven by VYVGART's strong performance in MG and CIDP, including the seronegative MG launch. Pipeline progress and label expansions are set to sustain long-term growth, with robust financials and disciplined capital allocation.

Based on 

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [ARGX.US](https://longbridge.com/en/quote/ARGX.US.md)

## Related News & Research

- [ARGX: Strong growth in MG and CIDP, pipeline expansion, and innovation drive long-term immunology leadership](https://longbridge.com/en/news/298340062.md)
- [Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today](https://longbridge.com/en/news/298074699.md)
- [VOR: Phase III trials for Telitacicept in MG and Sjögren's show strong progress and market potential](https://longbridge.com/en/news/298487080.md)
- [Jefferies Keeps Their Buy Rating on arGEN X (0QW0)](https://longbridge.com/en/news/297985115.md)
- [Vor Bio completes enrollment in Phase 3 UPSTREAM MG trial for telitacicept in generalized myasthenia gravis](https://longbridge.com/en/news/298307070.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**